Brain Scientific Inc. (BRSF) Offers Solutions for COVID-19 EEG Accessibility
- Seizures have been common in hospitalized COVID-19 patients, and the death rate higher in those who experienced the seizures
- Due to a shortage of PPE and limited contact, EEG accessibility was limited during the pandemic
- The NeuroCap can fill the gap in EEG accessibility during the pandemic and into the future, as more long-term studies are created
Brain Scientific (OTCQB: BRSF) is developing innovative and proprietary medical devices and software to bridge the widening gap in access to quality care. The Company’s first commercialized devices, the NeuroCap(TM) and NeuroEEG(TM), offer cost-effective and disposable substitutes to their traditional counterparts.
The NeuroCap is FDA-cleared, minimizes cross-contamination, and can be administered by clinical staff of any level. With over one-third of coronavirus patients reporting neurological symptoms, more patients must receive EEGs that allow for limited contact and ease of use. The NeuroCap takes less than five minutes to set up, can remain on the patient’s head for up to four hours, and is disposable, making it more sanitary than the bulky wires of traditional EEGs that require constant cleaning.
Throughout the pandemic, seizures have been common in hospitalized COVID-19 patients, and the death rate higher in those who experienced the seizures (https://nnw.fm/SskV2).
“Patients as a whole are at significantly high risk of seizures when they’re critically ill in the ICU,” stated Richard Temes, a neurologist at Northwell Health in New York in an article published by The Scientist. “The only way that you detect these seizures oftentimes is by capturing the seizure activity on the EEG.”
Monitoring a patient’s brain waves lets the physician know how best to treat the patient. However, due to a shortage of personal protective equipment (“PPE”) and the need to limit interaction with patients, only the sickest patients were receiving EEGs during the beginning of the pandemic.
With time it was discovered that what was thought to be only a respiratory syndrome had a significant effect throughout the body and the brain, resulting in a wide range of cognitive effects from brain fog to strokes. According to The Scientist, the number of seizures was similar to the number reported for patients hospitalized with other illnesses. The seizures might not be COVID attacking the brain or causing brain damage, but rather the severity of the disease. Right now, it is unknown how COVID-19 affects the brain. More studies are needed.
The NeuroCap is ideal for this type of study for several reasons:
- Pre-gelled fixed electrode placement makes it easy to apply by frontline healthcare workers, no specialized EEG technicians needed (https://nnw.fm/ZDo0u)
- Application takes less than five minutes, limiting the time of contact with the patient
- Disposable and sanitary
- Available in multiple sizes, including pediatrics
- Cost-effective
Brain Scientific is working toward improving patients’ access to neurological care. The NeuroCap can fill the gap in EEG testing availabilities during the COVID pandemic and beyond as more long-term studies are created.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Seizures have been common in hospitalized COVID-19 patients, and the death rate higher in those who experienced the seizures
- Due to a shortage of PPE and limited contact, EEG accessibility was limited during the pandemic
- The NeuroCap can fill the gap in EEG accessibility during the pandemic and into the future, as more long-term studies are created
Brain Scientific (OTCQB: BRSF) is developing innovative and proprietary medical devices and software to bridge the widening gap in access to quality care. The Company’s first commercialized devices, the NeuroCap(TM) and NeuroEEG(TM), offer cost-effective and disposable substitutes to their traditional counterparts.
The NeuroCap is FDA-cleared, minimizes cross-contamination, and can be administered by clinical staff of any level. With over one-third of coronavirus patients reporting neurological symptoms, more patients must receive EEGs that allow for limited contact and ease of use. The NeuroCap takes less than five minutes to set up, can remain on the patient’s head for up to four hours, and is disposable, making it more sanitary than the bulky wires of traditional EEGs that require constant cleaning.
Throughout the pandemic, seizures have been common in hospitalized COVID-19 patients, and the death rate higher in those who experienced the seizures (https://nnw.fm/SskV2).
“Patients as a whole are at significantly high risk of seizures when they’re critically ill in the ICU,” stated Richard Temes, a neurologist at Northwell Health in New York in an article published by The Scientist. “The only way that you detect these seizures oftentimes is by capturing the seizure activity on the EEG.”
Monitoring a patient’s brain waves lets the physician know how best to treat the patient. However, due to a shortage of personal protective equipment (“PPE”) and the need to limit interaction with patients, only the sickest patients were receiving EEGs during the beginning of the pandemic.
With time it was discovered that what was thought to be only a respiratory syndrome had a significant effect throughout the body and the brain, resulting in a wide range of cognitive effects from brain fog to strokes. According to The Scientist, the number of seizures was similar to the number reported for patients hospitalized with other illnesses. The seizures might not be COVID attacking the brain or causing brain damage, but rather the severity of the disease. Right now, it is unknown how COVID-19 affects the brain. More studies are needed.
The NeuroCap is ideal for this type of study for several reasons:
- Pre-gelled fixed electrode placement makes it easy to apply by frontline healthcare workers, no specialized EEG technicians needed (https://nnw.fm/ZDo0u)
- Application takes less than five minutes, limiting the time of contact with the patient
- Disposable and sanitary
- Available in multiple sizes, including pediatrics
- Cost-effective
Brain Scientific is working toward improving patients’ access to neurological care. The NeuroCap can fill the gap in EEG testing availabilities during the COVID pandemic and beyond as more long-term studies are created.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
